Skip to main content
Equibles

Caligan Partners LP

Position in AGIO — Agios Pharmaceuticals, Inc.

CIK 1727492 NEW YORK, NY
Back to AGIO Full portfolio

Position in AGIO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
15 quarters on record

Common Shares in AGIO Over Time

Shares Held

Position Value (USD)

Derivatives in AGIO

reported options exposure · as of Jun 30, 2026
CallValue
$3,339,900
CallShares
90,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Caligan Partners LP holds $1,404,383,722 across 23 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 1,961,795 $367,404,967
2 ABVX
Abivax S.A.
 1,557,924 $207,608,952
3 PCVX
Vaxcyte, Inc.
 2,188,636 $127,225,410
4 EXEL
Exelixis, Inc.
 1,553,262 $84,512,985
5 TNGX
Tango Therapeutics, Inc.
 2,500,103 $78,153,219
6 AVTX
Avalo Therapeutics, Inc.
 3,163,866 $58,468,243
7 XENE
Xenon Pharmaceuticals Inc.
 889,944 $53,717,019
8 ADMA
Adma Biologics, Inc.
 5,725,007 $47,918,308

All Filings in AGIO

Export CSV
16 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,339,900 90,000
2026-03-31 $3,044,700 90,000
2025-12-31 $2,449,800 90,000
2025-09-30 $39,136,500 975,000
2025-09-30 $45,406,568 1,131,205
2025-06-30 $35,630,041 1,071,258
2025-03-31 $20,547,504 701,280
2024-12-31 $20,579,560 626,280
2024-09-30 $25,756,826 579,717
2024-06-30 $22,194,338 514,711
2024-03-31 $14,172,949 484,711
2023-12-31 $9,839,620 441,833
2023-09-30 $119,616 4,833
2023-06-30 $136,870 4,833
2023-03-31 $99,529 4,333
2022-12-31 $121,670 4,333